NEW
YORK, July 30, 2024 /PRNewswire/ -- The
global drug discovery informatics market size is
estimated to grow by USD 7.28 billion
from 2024-2028, according to Technavio. The market is estimated to
grow at a CAGR of over 18.17% during the forecast
period. Increasing r and d investments by pharmaceutical and
biopharmaceutical companies is driving market
growth, with a trend towards increasing number of
clinical trials. However, high setup cost of drug discovery
informatics poses a challenge. Key market players include
Aragen Life Sciences Pvt. Ltd., Certara Inc., Charles River
Laboratories International Inc., ChemAxon Ltd., ChemBridge Corp.,
Collaborative Drug Discovery Inc., Cresset BioMolecular Discovery
Ltd., Curia Global Inc., Dassault Systemes SE, Eurofins Scientific
SE, Evotec SE, Infosys Ltd., Insilico Medicine, International
Business Machines Corp., Jubilant Pharmova Ltd., Melissa Inc.,
OpenEye Scientific Software Inc., PerkinElmer Inc., Schrodinger
Inc., Selvita SA, and Thermo Fisher Scientific Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Drug Discovery
Informatics Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
18.17%
|
Market growth
2024-2028
|
USD 7287.7
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
15.63
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
29%
|
Key
countries
|
US, Germany, UK, China,
and France
|
Key companies
profiled
|
Aragen Life Sciences
Pvt. Ltd., Certara Inc., Charles River Laboratories International
Inc., ChemAxon Ltd., ChemBridge Corp., Collaborative Drug Discovery
Inc., Cresset BioMolecular Discovery Ltd., Curia Global Inc.,
Dassault Systemes SE, Eurofins Scientific SE, Evotec SE, Infosys
Ltd., Insilico Medicine, International Business Machines Corp.,
Jubilant Pharmova Ltd., Melissa Inc., OpenEye Scientific Software
Inc., PerkinElmer Inc., Schrodinger Inc., Selvita SA, and Thermo
Fisher Scientific Inc.
|
Market Driver
Pharmaceutical and biotech companies, along with research
institutes, are concentrating on executing clinical trials to
discover innovative treatments for chronic conditions and
infectious diseases. These trials are crucial in the drug discovery
and development process to assess a new drug molecule's safety and
efficacy, leading to regulatory approval for commercialization.
However, data collection from clinical trials can introduce
unnecessary risks, costs, and complexity. Data from early drug
development stages is also essential during clinical trials. An
efficient clinical data integration platform simplifies the process
by integrating, standardizing, and aggregating data from various
sources in real-time. This enables pharmaceutical firms to make
informed decisions about potential drug molecules. Drug discovery
informatics solutions optimize clinical trial performance. Market
players, such as Infosys Ltd., are innovating clinical trial supply
management (CTSM) solutions to streamline clinical trial processes
and boost the drug development process's productivity. These
advancements are anticipated to fuel the global drug discovery
informatics market's growth in the forecast period.
The Drug Discovery Informatics market is experiencing
significant growth due to the increasing focus on Hit-to-Lead
optimization and the development of new treatments for various
diseases. Healthcare infrastructure investments are driving the
demand for advanced data mining and analytics technologies to
support drug development. Precision medicines are at the forefront
of this trend, with medical scientists leveraging large datasets to
create effective treatments tailored to patient demographics and
medical conditions. AI algorithms and informatics solutions are
essential tools for processing and analyzing drug discovery data,
enabling the identification of novel therapeutic compounds for
chronic diseases. Financial investments in hardware and specialized
expertise are fueling technological advancements in areas like
target discovery sequencing and bioinformatics solutions. The
biotechnology industry is also investing in AI and computational
drug discovery to streamline workflows and accelerate the
development of new medications for rare diseases and orphan drug
research. Overall, the market for drug discovery informatics is
expected to continue growing as technological innovations improve
the effectiveness of medical care and enable more precise and
personalized treatments.
Discover 360° analysis of this market. For
complete information, schedule your consultation - Book
Here!
Market Challenges
• Drug discovery
and development involve generating large amounts of data, making
drug discovery informatics a crucial tool for pharmaceutical and
biopharmaceutical companies. This technology facilitates the
integration and aggregation of heterogeneous data, streamlining the
drug discovery process from target identification to
commercialization. Drug discovery and design processes are costly,
with an average total cost of development ranging from USD800 million to USD2
billion. Drug discovery informatics plays a significant role
in reducing these costs through computer-aided drug design (CADD)
and other advanced technologies. However, the cost of drug
discovery informatics is influenced by factors such as software,
personnel, and instruments. For instance, laboratory information
management systems (LIMS) and high-throughput screening (HTS)
software can cost up to USD25,000 and
USD100,000, respectively. The high
costs associated with drug discovery informatics may limit its use
in smaller laboratories, potentially hindering market growth during
the forecast period.
• The Drug
Discovery Informatics market is experiencing significant growth due
to the increasing demand for precision medicine and improved
medical care. The effectiveness of treatments relies heavily on
understanding patient groups through genetic and molecular
profiling. Technological advancements, such as gene sequencing and
next-generation sequencing, have revolutionized the biotechnology
industry, leading to the discovery of novel medications for rare
diseases and orphan drug research. Informatics software plays a
crucial role in data gathering, storage, and visualization for
scientific research. With the rise of cloud-based technology and
cloud computing, data processing and storage have become more
accessible and cost-effective. The healthcare IT industries and
innovative pharmaceuticals are leveraging informatics software to
design clinical trials, analyze sequence data, and model drug
molecules using in-silico tools. The SARS-COV-2 vaccines and
research on infectious and cancer diseases have further accelerated
the market's growth. Despite these advancements, challenges remain,
including the high cost of informatics software, the need for
high-performance computing, and the complexity of data analysis
platforms. Web services, sequence analysis platforms, bioinformatic
solutions, nucleic acids, proteins, and genes are all integral
components of the drug discovery process. In summary, the Drug
Discovery Informatics market is a dynamic and evolving landscape
that is essential for the development of new treatments and
medications.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This drug discovery informatics market report extensively covers
market segmentation by
- Application
- 1.1 Discovery informatics
- 1.2 Development informatics
- Solution
- 2.1 Software
- 2.2 Services
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Discovery informatics- The drug discovery
process is a critical phase in the development of new medicines,
involving the generation of vast amounts of data and information.
Two primary steps in this process are identification and validation
of leads, which are identified through various target classes using
technologies such as high throughput screening, molecular modeling,
medicinal chemistry, and structural biology. Drug discovery
informatics plays a pivotal role in managing and analyzing this
data, consisting of identification, validation, assay development,
and lead generation informatics. Major players in the global drug
discovery informatics market include IBM, Schrodinger, Certara,
PerkinElmer, Collaborative Drug Discovery, and Evote. These
companies offer innovative solutions that enable researchers to
view essential chemistry and biology data during the drug discovery
process. The pharmaceutical industry's adoption of these solutions
is increasing due to their ease of use, affordability, multi-domain
capabilities, and intellectual property protection features.
Eurofins Scientific, a leading provider of drug discovery services
to the pharmaceutical and biotech industries, has expanded its
offerings in the drug discovery informatics market by acquiring
various organizations. This acquisition is expected to enhance
Eurofins Scientific's product offerings and provide better services
associated with drug discovery informatics. The identification,
validation, and lead generation process using a wide range of
technologies will continue to drive the growth of the discovery
informatics segment in the forecast period.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2017-2021) - Download a Sample Report
Research Analysis
The Drug Discovery Informatics market is a dynamic and
innovative sector that leverages technological advancements to
revolutionize medical care through precision medicine. This
approach, which focuses on effectiveness for individual patients
based on genetic and molecular profiling, is transforming the way
we treat various medical conditions, including rare diseases and
orphan drug research. Informatics software plays a pivotal role in
this process by facilitating data gathering, storage, and analysis.
Technological innovations, such as gene sequencing and molecular
modeling, enable the identification of novel medications and the
design of clinical trials. Sequence analysis platforms and
bioinformatic solutions are crucial tools for interpreting genome
sequencing data, genes, nucleic acids, proteins, and molecular
structures. Patient groups and medical professionals benefit from
these advancements, as they can tailor treatments to each patient's
unique genetic makeup. The biotechnology industry is at the
forefront of these developments, driving progress in drug discovery
and medical research. Data collection, data visualization, and
clinical trial design are essential components of this process,
ensuring that the most effective medications reach the market.
Market Research Overview
The Drug Discovery Informatics market is experiencing
significant growth due to the increasing focus on precision
medicine and medical care. With advancements in genetic and
molecular profiling, patient groups are playing a more active role
in drug discovery. Technological advancements, such as gene
sequencing and next-generation sequencing, are enabling the
identification of novel medications for rare diseases and orphan
drug research. Informatics software is essential for data
gathering, storage, and visualization, allowing medical scientists
to analyze large datasets and discover new drug molecules.
Cloud-based technology and high-performance computing are
revolutionizing drug development by providing affordable and
accessible solutions for scientific research. The biotechnology
industry is investing heavily in informatics solutions for
infectious diseases, cancer, and chronic diseases, utilizing AI
algorithms and bioinformatics tools for hit discovery, hit-to-lead
optimization, and clinical trial design. The healthcare IT
industries are also playing a crucial role in this field, providing
innovative pharmaceuticals with the necessary infrastructural
technology and specialized expertise to advance drug discovery. The
market for drug discovery informatics is expected to continue
growing as financial investments increase and the need for
effective treatments for various diseases continues to rise.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Application
-
- Discovery Informatics
- Development Informatics
- Solution
-
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/drug-discovery-informatics-market-size-is-set-to-grow-by-usd-7-28-billion-from-2024-2028--increasing-r-and-d-investments-by-pharmaceutical-and-biopharmaceutical-companies-boost-the-market-technavio-302209454.html
SOURCE Technavio